Antagonism of B3 adrenoceptor for the treatment of cancer immune tolerance

The invention relates to the use of beta-blocking compounds, in particular the antagonist of β3 adrenoceptor (β3-ARs), for the treatment of immune-tolerance associated with pathological states, such as cancer.

Settore:

Life sciences

Research Institution:

Università degli Studi di Firenze

Publication number:

WO2018116227A1

TRL:

3

Technologies, Systems, Applications:

New drugs development,
Biotechnologies

Technological Priority:

Biomedical, pharmaceutical, pharmacological technologies,
Biotechnologies for health
Pubblicato il:
Torna in cima alla pagina